Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $5.00 → $1.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 6/22/2022 | $15.00 | Buy | H.C. Wainwright |
| 4/6/2022 | $10.00 | Buy → Hold | Truist |
| 1/28/2022 | $9.00 | Outperform | Oppenheimer |
| 11/24/2021 | $9.00 | Equal-Weight | Morgan Stanley |
| 10/19/2021 | $12.00 | Buy | Truist Securities |
FLORHAM PARK, N.J., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that the Nasdaq Listing Qualifications Hearings Panel (the "Hearings Panel") has cancelled the previously scheduled hearing regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule"), as the Company has cured its filing delinquency. The matter is now closed, and Nasdaq has confirmed that Celularity's stock will continue to be listed and traded on The Nasdaq Stock Market. This resolution follows Nasdaq's prior notification on October 16, 2024, indicating that Celularity was not in compliance with the Ru
Celularity Raises Full Year 2024 Expected Net Sales Guidance to $54 Million to $60 Million, Compared to Previous Guidance of $50 Million to $56 MillionOctober Expected Net Sales of $8.3 Million to $8.9 Million Marks the Highest Single-Month Figure in its HistoryCelularity Filed its Second Quarter Form 10-Q and is Now Current With its Quarterly Report Filings FLORHAM PARK, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity") a regenerative and cellular medicine company, today announced that it has increased expected net sales guidance for the full year 2024 to $54 million to $60 million, up from $50 million to $56 million previously announced in February. Th
FLORHAM PARK, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, today announced that it has requested a hearing before the Nasdaq Hearings Panel (the "Hearings Panel") the Nasdaq Listing Qualifications Department's determination regarding Celularity's non-compliance with Nasdaq Listing Rule 5250(c)(1) (the "Rule") and to seek an additional extension to regain compliance. As previously announced, Celularity received formal notice from Nasdaq on August 22, 2024, indicating non-compliance with the Rule due to the delayed filing of its quarterly reports on Forms 10-Q for the periods ended March 31, 2024, and Ju
Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously
Oppenheimer downgraded Celularity from Outperform to Perform
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
3 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
DEF 14A - Celularity Inc (0001752828) (Filer)
NT 10-Q - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that the Journal for ImmunoTherapy of Cancer, a peer-reviewed online journal of the Society for Immunotherapy of Cancer, published data highlighting the potential advantages of Celularity's T-Cell platform for future immunotherapies including chimeric antigen receptor (CAR-T) therapies. The data compared CAR-T cells derived from Celularity's proprietary T cell platform with CAR-T cells derived from healthy adult peripheral blood mononuclear cells (PBMCs). CAR-T cells generated from its T-Cell platf
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi
FLORHAM PARK, N.J., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (the "Company"), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today the appointment of Richard J. Berman, to its Board of Directors. Mr. Berman is an experienced public company director whose career spans over 40 years of venture capital, senior management, and merger and acquisitions experience. He has served as a director and/or officer of over a dozen public and private companies in the last five years, six of which have reached over one billion dollars in market value. Previously, Mr. Berman worked at Gol
FLORHAM PARK, N.J., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) (Celularity), a biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies and advanced biomaterial products, today announced the appointment of Geoffrey Shiu Fei Ling, M.D., Ph.D. to its Board of Directors. Dr. Ling, a distinguished academic and military physician-scientist with a strong background in regenerative medicine and a deep commitment to advancing healthcare, will bring invaluable expertise and insights to Celularity as it continues to pioneer innovative therapies for patients in need. Throughout his career, Dr. Ling has made significant contributions to regenera
FLORHAM PARK, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell and biomaterial therapies, today announced that Paul Graves has been appointed Senior Vice President, Chief Communications Officer, effective January 2, 2023. Mr. Graves is a seasoned communications professional who brings more than 30 years of strategic communications experience in the biopharmaceutical industry. He has deep expertise in corporate reputation, global research and development, product launch and promotion, investor relations and public affairs. He will provide senior strategic communications leadership for C
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13D/A - Celularity Inc (0001752828) (Subject)